share_log

益方生物(688382.SH)拟购买不超3个目标抗体对应专有技术 加快新药开发进度

Yifang Biotechnology (688382.SH) plans to purchase proprietary technology corresponding to not more than 3 target antibodies to accelerate the progress of new drug development.

Zhitong Finance ·  Oct 21, 2024 17:29

Yifang Biotechnology (688382.SH) announced that the company plans to sign a transfer agreement with Lyvgen Biopharma Holdings Limited and its controlled companies.

Zhithong Finance APP news, Yifang Biotechnology (688382.SH) announced that the company plans to sign a "Transfer Agreement" with Lyvgen Biopharma Holdings Limited and its controlled companies (referred to as "Lyvgen", "the seller"). Lyvgen intends to transfer proprietary technology corresponding to no more than 3 target antibodies to the company, grant relevant licensed patent rights, and transfer other necessary materials, with a total transaction amount not exceeding RMB 1.5 million.

This related transaction is necessary for the development and operation of the company business, beneficial for the company to improve research and development efficiency, accelerate the progress of new drug development, and further expand the existing product pipeline.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment